Mounjaro: once-weekly injection for type 2 diabetes and weight management

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 6:26 PM ET. Details in the imprint.

Mounjaro, the brand name for tirzepatide from Eli Lilly and Co., is a once-weekly injectable prescription medicine originally approved by the US Food and Drug Administration (FDA) to improve blood sugar control in adults with type 2 diabetes. In the US, the same active ingredient tirzepatide is also marketed as Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition, making the molecule one of the most closely watched metabolic therapies among consumers and physicians. For many US patients, Mounjaro sits at the intersection of blood sugar management and significant weight loss potential, although only Zepbound carries an explicit obesity indication.

What Mounjaro does and how it is used in the US

Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist given as a subcutaneous injection once a week, with recommended dosing titrated over time to improve tolerability. According to the FDA prescribing information, the medicine is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and is not approved for use in patients with type 1 diabetes. Lilly offers Mounjaro in a pre-filled, single-dose pen device designed for at-home administration, with several dosage strengths, such as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, taken once weekly. The pens are intended for subcutaneous injection in the abdomen, thigh, or upper arm, and patients are advised to rotate injection sites.

In pivotal SURPASS clinical trials, tirzepatide demonstrated substantial reductions in HbA1c and body weight compared with comparators such as insulin degludec and semaglutide in adults with type 2 diabetes. Based on published data, participants receiving higher doses of tirzepatide achieved mean weight reductions of more than 10 percent of baseline body weight in some studies, although the primary endpoint in the Mounjaro diabetes program was glycemic control rather than weight loss per se. These outcomes have helped position Mounjaro as a therapy that not only lowers blood glucose but also supports clinically meaningful weight loss in many patients, an attribute that has driven strong interest among US consumers living with both diabetes and obesity. For obesity specifically, the tirzepatide brand Zepbound is the product with FDA approval for chronic weight management, while Mounjaro remains labeled primarily for type 2 diabetes.

For US patients, a key practical detail is that Mounjaro is supplied as ready-to-use pens that do not require mixing or reconstitution, which simplifies weekly injections compared with some older injectable diabetes therapies. The pens come in cartons containing multiple single-dose devices, and they must be stored refrigerated before first use, within a temperature range specified in the prescribing information, though limited room-temperature storage for a defined period is typically allowed. Lilly provides detailed injection instructions and patient support resources on its official Mounjaro product site, including guidance on how to dispose of used pens safely through sharps containers and local disposal programs. As with other GLP-1-related therapies, titration schedules usually start at 2.5 mg once weekly for four weeks before increasing in 2.5 mg increments as tolerated, but actual regimens are determined by healthcare professionals based on individual response.

Like other incretin-based medicines, Mounjaro carries safety warnings that US patients and caregivers are urged to review carefully with their healthcare providers. The FDA prescribing information includes a boxed warning about the risk of thyroid C-cell tumors observed in rodent studies with tirzepatide, although it is not known whether the medicine causes such tumors in humans. Because of this, Mounjaro is not recommended in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2. Common adverse reactions reported in clinical trials include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain, especially during the dose-escalation phase. The label also highlights risks of pancreatitis, gallbladder disease, hypoglycemia when used with insulin or sulfonylureas, acute kidney injury in the setting of severe gastrointestinal reactions, and potential diabetic retinopathy complications associated with rapid improvements in glycemic control.

US consumers considering discussion of Mounjaro with their physicians typically weigh the drug's benefits in glycemic control and weight reduction against these safety considerations and potential side effects. For people with type 2 diabetes who are already on metformin or other oral agents, Mounjaro is often introduced when additional A1c lowering is needed, or when weight gain from prior therapies is a concern. Insurance coverage and out-of-pocket costs can be significant factors: list prices for advanced diabetes injectables are high, but actual patient costs depend on commercial insurance formularies, Medicare coverage decisions, copay assistance, and manufacturer savings programs. Lilly publicly communicates that it offers savings cards and support programs for eligible US patients, allowing some commercially insured users to pay lower monthly amounts, while uninsured or Medicare patients may face higher expenses. Pharmacies such as CVS, Walgreens, and major supermarket chains typically stock Mounjaro, but supply constraints in the broader GLP-1 space have periodically led to limited availability for certain dosages, depending on region and demand.

From a product-portfolio perspective, Mounjaro and Zepbound sit at the heart of Eli Lilly's metabolic franchise, a key contributor to the company's revenue growth in recent years. Public financial reports from Lilly have highlighted rapid uptake of tirzepatide products in both diabetes and obesity segments, reflecting strong prescription trends in the US and other markets where approved. These dynamics are shaping Lilly's manufacturing and supply-chain investment decisions as the company commits additional capital to expand production capacity for incretin-based therapeutics to meet global demand. For individual consumers, the practical implication is that availability and waiting times for prescriptions may fluctuate, so pharmacy stock checks and early prescription refills can be important for continuous therapy.

Shares of Eli Lilly and Co. (US5324571083, ticker LLY) traded at $NNN.NN on NYSE on June 11, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.